---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031420"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:56:51.841711+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Atossa Q3 2023: cash $94M; two Phase 2 trials 80% enrolled; net loss details

## Summary
- Cash and cash equivalents $94.0M as of Sept 30, 2023.
- Two Phase 2 trials (Karisma-Endoxifen, I-SPY 2) at 80% enrollment; data expected H2 2024.
- R&D expense $4.5M in Q3 2023, down 13% YoY; G&A $3.0M, flat YoY.
- Interest income $1.3M in Q3 2023 vs $0.2M in Q3 2022 due to higher rates and balance.
- Jonathan Finn appointed to Board of Directors.

## SEC filing metadata
- accession: 0001437749-23-031420
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000143774923031420/0001437749-23-031420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000143774923031420/atos20231106c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031420
- JSON: https://secwatch.observer/filing/0001437749-23-031420.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031420.txt

## Key facts
- Earnings Releases
  ATOSSA THERAPEUTICS, INC. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended September 30, 2023 financial results and a Company update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774923031420/0001437749-23-031420-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.